Fabienne MacKay
10Patents
6h-index
8Co-inventors
55Inventor score
Filing activity: Apr 23, 1999 → May 15, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7083785B2 | Methods of treatment by administering an anti-BCMA antibody | Chemistry; Metallurgy | 86 | Expired |
| US6869605B2 | BAFF, inhibitors thereof and their use in the modulation of B-cell response | Human Necessities | 32 | Expired |
| US7255854B1 | Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases | Emerging Cross-Sectional Technologies | 12 | Expired |
| US9545086B2 | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders | Human Necessities | 10 | Active |
| US7309492B2 | Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of systemic lupus erythematosus | Emerging Cross-Sectional Technologies | 7 | Expired |
| US9650430B2 | Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA) | Chemistry; Metallurgy | 6 | Active |
| US7744891B2 | Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases | Emerging Cross-Sectional Technologies | 2 | Active |
| US10494416B2 | Methods of modulating immune responses using BCMA polypeptide | Chemistry; Metallurgy | 1 | Active |
| US8828669B2 | Methods of screening for a compound that inhibits the interaction between BAFF and BCMA | Chemistry; Metallurgy | 1 | Active |
| US8287874B2 | Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.